Slow Bull
The market, slowly. FRIDAY, 25 SEPTEMBER 2026

Aptevo Therapeutics Inc.

APVO Nasdaq SEC CIK 1671584
Follow Aptevo Therapeutics Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Net income −$6.4M −2.5% vs same quarter last year
EPS, diluted −$5.31 +96.5% vs same quarter last year
Operating cash flow −$5.5M +23.1% vs same quarter last year
Operating income −$6.4M −3.5% vs same quarter last year
Net income by quarter
−$5.1M
−$6.3M
−$6.4M
−$6.2M
−$7.5M
−$5.8M
−$6.7M
−$6.4M
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income12 fiscal years
  • Revenue
  • Net income
−$150M−$100M−$50M$0$50MFY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25-−$26M
FY24-−$24.1M
FY23-−$17.4M
FY22$3.1M$8M
FY21$12.3M−$28.5M
FY20$4.3M−$17.8M
FY19$32.4M−$40.4M
FY18$23.1M−$53.7M
FY17$14.7M$7M
FY16$10M−$112.4M
FY15$33.6M−$59.3M
FY14--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−1500%−1000%−500%0%500%FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25---
FY24---
FY23---
FY22-−919.7%257.8%
FY21-−174.1%−231.5%
FY20-−638.1%−411.9%
FY1938.5%−126.3%−124.7%
FY1851.4%−224%−232.8%
FY1765.8%−368.1%47.6%
FY16−24.9%−1389.8%−1125.8%
FY1549.6%−181.8%−176.5%
FY14---
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23-
FY22−$21.1M
FY21−$22.4M
FY20−$29.4M
FY19−$42.5M
FY18−$52.4M
FY17−$43M
FY16−$39.4M
FY15−$50.3M
FY14-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Aptevo Therapeutics
  • Healthcare median
−1500%−1000%−500%0%500%FY15FY17FY19FY21FY23FY25
Show the numbers
YearAptevo TherapeuticsHealthcare median
FY25-−40.6%
FY24-−60.7%
FY23-−97.1%
FY22257.8%−128.5%
FY21−231.5%−129.2%
FY20−411.9%−136.5%
FY19−124.7%−133.7%
FY18−232.8%−173.4%
FY1747.6%−176.7%
FY16−1125.8%−164.8%
FY15−176.5%−183.4%
FY14-−133%

News

No stories filed under Aptevo Therapeutics yet - coverage appears here as the news feed clusters it.